Last reviewed · How we verify
Gestinol (GESTODENE)
Gestinol (GESTODENE) is a small molecule modality targeting Cytochrome P450 3A5. Its commercial status and approved indications are unknown. As a small molecule, it is likely to be a potent inhibitor of its target enzyme, affecting various metabolic pathways. Further research is needed to determine its potential therapeutic applications and safety profile. Its pharmacokinetic properties include a half-life of 10.0 hours and bioavailability of 93%.
At a glance
| Generic name | GESTODENE |
|---|---|
| Target | Cytochrome P450 3A5, Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- "Quick-starting" of a New Combined Hormonal Contraceptive Pills, 15 mg Estetrol/3 mg Drospirenone VS 20 mcg Ethinylestradiol/75 mcg Gestodene Focusing on Ovulation Inhibition (NA)
- "Quick-starting" of a Quadriphasic Contraceptive Pills, 1 - 3 mg Estradiol Valerate/ 2 - 3 mg Dienogest VS 20 mcg Ethinylestradiol/75 mcg Gestodene Focusing on Ovulation Inhibition (NA)
- US Ovulation Inhibition Study in Obese Women (PHASE2)
- Study Investigating the Efficacy and Safety of a Contraceptive Patch for 13 Cycles (PHASE3)
- European Active Surveillance Study Comparing Regimens of Administration in Combined Hormonal Contraception
- Dienogest for Treatment of Adenomyotic Uteri (NA)
- OCP Pretreatment in PCOS Patients Undergoing ICSI Using Antagonist Protocol (PHASE1,PHASE2)
- Comparison of Coagulation Profiles Between Zoely and Minidoz: RCT (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |